Author

Xinzhe Yu

Baylor College of MedicineORCID 0000-0002-4145-1858Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Approach:mechanistic / dynamical model· 1

Frequent Co-Authors

Ariella B. HankeriD· 1 shared Atreyi MukherjiiD· 1 shared Carla R. TiradoiD· 1 shared Carlos L. ArteagaiD· 1 shared Choushi WangiD· 1 shared Felix Yi-Chung FengiD· 1 shared Ganesh V. RajiD· 1 shared Garrett WainwrightiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ariella B. HankerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiophysicsbioRxivPreprintJun 9, 2026

Dynamic Gating Mechanism of the b0,+AT-Mediated Arg Transport: Insights from ASMD Simulations

Qinjie Tang, Xing Zhamg, Xuhua Li…·Shengli Zhang

This paper identifies residue W230 as a dynamic gate in b0,+AT that regulates arginine transport through side chain flipping, using molecular dynamics simulations.

DOI 10.64898/2026.06.03.729795

structural biologymechanistic / dynamical model

𝕏 PostBluesky

Cancer BiologyCancer DiscoveryPeer-reviewedApr 8, 2024

ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers

Yaru Xu, Yuqiu Yang, Zhaoning Wang…·Ping Mu

This study shows ZNF397 loss leads to TET2-driven epigenetic changes, lineage plasticity, and resistance to AR-targeted therapies in AR-dependent cancers, with TET2 inhibitors reversing resistance.

50 citationstop 2%

humanbulk RNA-seq

𝕏 PostBluesky